Thor Medical Stock

NANOV

NO0010597883

Biotechnology & Medical Research

Market Closed - Oslo Bors 10:45:00 2026-09-24 EDT			5-day change	1st Jan Change
4.595 ^NOK	-0.65%		-2.75%	-12.48%

08-28	Thor Medical ASA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-28	Thor Medical ASA, H1 2026 Earnings Call, Aug 28, 2026

Last Transcript: Thor Medical

Thor Medical ASA, H1 2026 Earnings Call, Aug 28, 2026

08-28

More transcripts

News in other languages: Thor Medical

08-20	Avis d'analystes du jour : ça bouge sur Michelin, Sartorius, Pandora et Merck KGaA
22-06-02	Actualización de las fuertes variaciones del día: EcoOnline despierta su sector, Klöckner ajuste después de dividendo
22-06-02	Point sur les fortes variations du jour : Saint-Gobain réveille son secteur, Esker trop prudent
21-02-19	Avis d'analystes du jour : L'Oréal, Air France KLM, Nestlé, Orange, Campari, Moncler, BioMérieux, Stratec...
21-02-19	Des PMI et des sorcières pour terminer la semaine

More news

Managers and Directors: Thor Medical

Manager	Title	Age	Since
Jasper Kurth CEO	Chief Executive Officer	41	2024-07-31
Brede Høyland Ellingsæter DFI	Director of Finance/CFO	37	2023-06-30
Sindre Hassfjell CTO	Chief Tech/Sci/R&D Officer	-	2023-05-31

Director	Title	Age	Since
Mimi Kristine Berdal BRD	Director/Board Member	67	2023-06-27
John Andersen CHM	Chairman	59	-
Jens Gisle Schnelle BRD	Director/Board Member	-	2025-04-23

More insiders

Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-24	NOK 4.595	-0.65%	2,275,305
26-09-23	NOK 4.625	-1.49%	3,279,374
26-09-22	NOK 4.695	+0.64%	4,979,238
26-09-21	NOK 4.665	+1.30%	3,133,081
26-09-18	NOK 4.605	-2.54%	3,295,870

Real-time Oslo Bors

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

SELL

Number of Analysts

Last Close Price

4.625NOK

Average target price

4.200NOK

Spread / Average Target

-9.19%

Consensus

EPS Estimates

Revisions to estimates

Annual profits - Rate of surprise

Company calendar

Market Cap	1.95B 205M 181M 170M 155M 290M 19.71B 293M 2.04B 792M 10.03B 771M 754M 32.64B	P/E 2026 *	-23.1x	P/E 2027 *	-38.5x
Enterprise Value	2.15B 226M 199M 187M 171M 320M 21.69B 322M 2.25B 871M 11.04B 848M 830M 35.93B	EV / Sales 2026 *	108x	EV / Sales 2027 *	14.9x
Free-Float	76.15%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Oslo Bors	NANOV	Real-time
CBOE	NANOo	Real-time
London S.E.	0R6Y	End-of-day quote
Nasdaq Stockholm	NANOVO	Delayed
Deutsche Boerse AG	8NN	Delayed
London S.E.	0R6Y	Delayed
CBOE	0R6Y	Real-time
Börse Stuttgart	8NN	Delayed
Boerse Muenchen	8NN	Real-time
Tradegate	8NN	Real-time
Berne S.E.	8NN	End-of-day quote

08-28	Thor Medical ASA Reports Earnings Results for the Half Year Ended June 30, 2026	CI
08-28	Thor Medical ASA, H1 2026 Earnings Call, Aug 28, 2026
08-25	Thor Medical's COO, CFO Transitions to Dedicated COO Role	MT
08-24	Thor Medical Asa CFO Brede Ellingsæter to Transition into Full-Time COO Role	CI
08-18	Thor Medical Asa Alphaone Facility Officially Opened by Norwegian Prime Minister Jonas Gahr Støre	CI
08-05	Thor Medical Completes Maiden Thorium-228 Isotope Delivery from AlphaOne Plant	MT
08-04	Thor Medical Asa Completes First Customer Delivery from Alphaone Production Facility	CI
07-30	Thor Medical ASA Starts Commercial Production At AlphaOne Facility	CI
06-16	Thor Medical ASA Announces Retirement of Alf Bjørseth from EVP Business Development, Effective June 30, 2026	CI
05-29	Thor Medical ASA Enters Collaboration and Supply Agreement With Minerva Imaging	CI
05-29	Thor Medical Lands Deal to Supply Cancer Treatment Isotope	MT
05-29	Thor Medical enters partnership agreement with Minerva Imaging	RE
05-28	Thor Medical, Eckert & Ziegler Close Deal for Lead-212 Supply	MT

09-22	Thor Medical ASA: Cancellation of Subsequent Offering	PU
09-11	Thor Medical ASA: Completed Redelivery of Shares	PU
09-10	Thor Medical ASA: Primary Insider Notification in Relation to Redelivery of Shares	PU
09-10	Thor Medical ASA: Disclosure of Large Shareholding	PU
09-10	Thor Medical : Share Capital Increase in Relation to the Private Placement and the Retail Offering is Registered	PU

1 day	-0.65%
1 week	-2.75%
Current month	-19.10%
1 month	-33.50%
3 months	+5.51%
6 months	+1.10%
Current year	-12.48%

Thor Medical Stock

Stocks

NANOV

NO0010597883

Biotechnology & Medical Research

Valuation: Thor Medical

Chart: Thor Medical

Latest news: Thor Medical

Last Transcript: Thor Medical

Press Releases: Thor Medical

News in other languages: Thor Medical

Quotes and Performance

Price Extremes

Managers and Directors: Thor Medical

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Analysts' Consensus

Annual profits - Rate of surprise

1 week	4.56	4.9
1 month	4.56	7.12
Current year	3.88	7.12
1 year	3.18	7.12
3 years	0.85	7.12
5 years	0.85	7.12
10 years	0.85	7.12

Date	Insider	Type	Main position	Quantity	% Market Cap.
6/26/25	Scatec Innovation AS	Others	Company	31,577,399	10.0434%
6/18/25	Scatec Innovation AS	Buy	Company	3,000,000	0.9542%
5/2/25	Jens Gisle Schnelle	Exercice	Director	164,641	0.0524%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
THOR MEDICAL	-0.65%	-2.75%	+27.82%	+230.58%	206M
WUXI APPTEC CO., LTD.	-3.30%	+2.97%	+54.99%	+104.15%	74.18B
ARGENX SE	-0.12%	-3.82%	+34.21%	+74.94%	59.55B
INSMED INCORPORATED	+1.27%	-3.44%	-15.09%	+364.39%	25.84B
BIONTECH SE	+0.13%	+0.21%	-0.89%	-4.13%	24.73B
GENMAB A/S	-1.05%	+1.07%	+21.45%	-10.04%	20.87B
PHARMAESSENTIA CORPORATION	-1.70%	-4.15%	+147.82%	+325.69%	15.32B
EXELIXIS, INC.	+1.18%	-2.03%	+47.28%	+162.51%	14.06B
SUMMIT THERAPEUTICS INC.	+0.70%	-6.97%	-19.59%	+758.59%	13.12B
MADRIGAL PHARMACEUTICALS, INC.	-0.03%	-3.77%	+20.48%	+240.69%	11.85B
Average	-0.34%	-0.96%	+31.85%	+224.74%	25.97B
Weighted average by Cap.	-0.91%	-0.23%	+34.93%	+159.48%

	2026 *	2027 *
Net sales	20M 2.1M 1.85M 1.74M 1.59M 2.97M 202M 3M 20.91M 8.1M 103M 7.89M 7.72M 334M	145M 15.23M 13.4M 12.63M 11.52M 21.55M 1.46B 21.72M 152M 58.74M 744M 57.19M 55.95M 2.42B
Net income	-70M -7.35M -6.47M -6.1M -5.56M -10.4M -706M -10.49M -73.17M -28.36M -359M -27.61M -27.01M -1.17B	-44M -4.62M -4.07M -3.83M -3.5M -6.54M -444M -6.59M -46M -17.82M -226M -17.36M -16.98M -735M
Net Debt	197M 20.7M 18.2M 17.16M 15.66M 29.28M 1.99B 29.51M 206M 79.8M 1.01B 77.71M 76.02M 3.29B	201M 21.12M 18.57M 17.51M 15.97M 29.87M 2.03B 30.11M 210M 81.42M 1.03B 79.28M 77.56M 3.36B